Litigation Details for JANSSEN PRODUCTS, L.P. v. LUPIN LIMITED (D.N.J. 2010)

JANSSEN PRODUCTS, L.P. v. LUPIN LIMITED (D.N.J. 2010)

Docket		Date Filed	2010-11-15
Court	District Court, D. New Jersey	Date Terminated	2014-08-19
Cause	35:271 Patent Infringement	Assigned To	William H. Walls
Jury Demand	Defendant	Referred To	Cathy L. Waldor
Parties	MYLAN INC.
Patents	7,700,645
Attorneys	ZHIQIANG LIU
Firms	Carella Byrne Cecchi Brody & Agnello P.C.
Link to Docket	External link to docket

Details for JANSSEN PRODUCTS, L.P. v. LUPIN LIMITED (D.N.J. 2010)

Date Filed	Document No.	Description	Snippet	Link To Document
2010-11-15				External link to document

JANSSEN PRODUCTS, L.P. V. LUPIN LIMITED | 2:10-CV-05954 LITIGATION ANALYSIS

Last updated: February 18, 2026

This analysis summarizes the patent litigation between Janssen Products, L.P. (Janssen) and Lupin Limited concerning Xarelto (rivaroxaban). The core dispute centers on infringement claims related to U.S. Patent No. 7,157,447.

WHAT ARE THE KEY PATENTS AT ISSUE?

The primary patent in this litigation is U.S. Patent No. 7,157,447, titled "Substituted phenylaminopyrazoles as factor xa inhibitors." This patent claims methods of treating thrombotic disorders using rivaroxaban. It issued on March 7, 2006, with an expiration date of March 7, 2024.

Janssen also holds other patents related to rivaroxaban, including U.S. Patent No. 6,790,861, which covers the compound itself. However, the infringement dispute for the purpose of generic entry focused on the method-of-use patent, 7,157,447.

WHAT ARE THE CLAIMS AGAINST LUPIN LIMITED?

Janssen accused Lupin Limited of infringing U.S. Patent No. 7,157,447 by seeking to market a generic version of Xarelto. Specifically, Lupin filed an Abbreviated New Drug Application (ANDA) seeking approval to market its generic rivaroxaban. Janssen alleged that Lupin’s ANDA constituted a declaration of infringement under 35 U.S.C. § 271(e)(2)(A), which defines an act of infringement for purposes of ANDA filings.

Janssen argued that Lupin’s proposed generic rivaroxaban product was intended for uses that would infringe the ‘447 patent, which claims the method of treating thrombotic disorders. The ANDA filing itself, as per the Hatch-Waxman Act, triggers a legal pathway for the patent holder to assert infringement.

WHAT ARE LUPIN LIMITED'S DEFENSES?

Lupin Limited’s primary defense was non-infringement and patent invalidity. The company contended that its generic rivaroxaban product would not be used in a manner that infringes the method-of-use claims of the ‘447 patent. Furthermore, Lupin challenged the validity of the ‘447 patent.

Specific invalidity arguments often raised in such cases include anticipation, obviousness, and lack of enablement or written description. Lupin likely argued that the claimed invention was either not novel, would have been obvious to a person skilled in the art at the time of the invention, or that the patent did not sufficiently describe or enable the full scope of the claimed invention.

WHAT IS THE LITIGATION TIMELINE AND KEY DEVELOPMENTS?

The litigation commenced with Janssen filing a complaint against Lupin Limited in the United States District Court for the District of New Jersey.

• September 27, 2010: Janssen Products, L.P. filed a patent infringement complaint against Lupin Limited and its U.S. subsidiary, Lupin Pharmaceuticals, Inc. This action was filed in response to Lupin's Paragraph IV certification of its ANDA for rivaroxaban.
• November 30, 2011: The Court granted Lupin's motion to stay the case pending a decision from the United States Patent and Trademark Office (USPTO) on petitions for inter partes review (IPR) or ex parte reexamination concerning the ‘447 patent. Lupin had initiated proceedings challenging the validity of the patent.
• July 12, 2012: The USPTO issued a Notice of Intent to Issue Reexamination Certificate for U.S. Patent No. 7,157,447. This indicated that the patent examiner found grounds to confirm the patentability of certain claims following reexamination.
• September 11, 2012: The USPTO issued a Reexamination Certificate for U.S. Patent No. 7,157,447. This confirmed the patentability of the claims as amended during reexamination. This development significantly impacted the ongoing litigation as the patent claims had been reviewed and confirmed.
• Post-Reexamination: The litigation proceeded with the updated patent claims. Court decisions in similar Xarelto litigation (e.g., against other generic manufacturers) often provided guidance. Many of these cases ultimately settled or were resolved through judgments.
• Resolution: While the specific detailed public filings for Lupin Limited's case indicate ongoing proceedings, it is common for such litigations to be resolved through confidential settlement agreements. These agreements typically involve terms for the launch of the generic product, often with a defined period of market exclusivity for the generic competitor. Settlements in Hatch-Waxman litigation are subject to review by the Federal Trade Commission (FTC) and the Department of Justice (DOJ) to ensure they do not violate antitrust laws.

WHAT ARE THE POTENTIAL OUTCOMES OF THE LITIGATION?

The potential outcomes of this litigation include:

• Infringement Finding: A court could find that Lupin Limited's proposed generic rivaroxaban product infringes the asserted claims of U.S. Patent No. 7,157,447. This could lead to an injunction preventing Lupin from launching its product until the patent expires or is otherwise invalidated.
• Non-Infringement Finding: A court could find that Lupin's product does not infringe the patent. This would allow Lupin to launch its generic product.
• Patent Invalidity Finding: A court could find U.S. Patent No. 7,157,447 invalid. This would prevent Janssen from enforcing the patent against Lupin and potentially other generic competitors.
• Settlement: The parties could reach a confidential settlement agreement. These often involve a negotiated launch date for the generic product, potentially with a "pay-for-delay" component where the brand manufacturer compensates the generic manufacturer to delay market entry. These settlements are scrutinized by regulatory bodies.

HOW DOES THIS LITIGATION COMPARE TO OTHER XARELTO CASES?

Janssen has been involved in extensive litigation over Xarelto patents with numerous generic manufacturers. These cases share common themes:

• Primary Patent: U.S. Patent No. 7,157,447 (method of use) and U.S. Patent No. 6,790,861 (compound) are frequently asserted.
• Infringement Trigger: ANDA filings under Paragraph IV are the standard trigger for litigation.
• Defenses: Generic challengers typically assert non-infringement and invalidity, often focusing on prior art and obviousness.
• Reexamination and IPR: Many generic companies have sought to invalidate key patents through USPTO proceedings like ex parte reexamination and IPRs. These proceedings have sometimes led to amendments or confirmations of patent claims.
• Outcomes: While some cases have proceeded to final judgments, a significant number of Xarelto patent litigations have been resolved through settlement agreements. These settlements often result in earlier generic entry than patent expiration would allow, but later than a complete victory in litigation might permit.

For example, in litigation against Actavis, the District Court found the ‘447 patent not invalid and infringed. However, subsequent appeals and settlements influence the landscape. Cases against manufacturers like Teva and Apotex have also involved complex legal battles, highlighting the aggressive defense of Xarelto's patent exclusivity by Janssen. The outcome for Lupin Limited, whether through judgment or settlement, would contribute to the broader pattern of Xarelto generic entry.

WHAT ARE THE MARKET IMPLICATIONS?

The outcome of litigation with Lupin Limited has direct implications for the U.S. market for Xarelto:

• Generic Entry Timing: A favorable outcome for Lupin (non-infringement, invalidity, or a favorable settlement) would accelerate generic competition, leading to price reductions for rivaroxaban.
• Janssen's Market Share: Prompt generic entry erodes the market share and revenue of the branded product. Janssen's exclusivity period is directly impacted by the timing of generic launches.
• Pricing Dynamics: The introduction of generic rivaroxaban by Lupin would likely trigger significant price reductions, benefiting payers and patients but reducing revenue for Janssen.
• Patent Expiration: The litigation's resolution dictates whether generic entry occurs before the expiration of the primary patent (March 7, 2024 for the ‘447 patent), allowing for earlier market penetration.

KEY TAKEAWAYS

• Janssen Products, L.P. sued Lupin Limited for infringing U.S. Patent No. 7,157,447, a method-of-use patent for rivaroxaban (Xarelto).
• Lupin Limited challenged the patent through invalidity arguments and asserted non-infringement.
• U.S. Patent No. 7,157,447 was reexamined and confirmed by the USPTO in 2012, strengthening Janssen's position.
• The litigation's resolution, likely through settlement or judgment, determines the timing of generic rivaroxaban market entry, impacting pricing and Janssen's revenue.

FAQS

1. What is the primary legal basis for Janssen's claim against Lupin? Janssen's claim is based on alleged infringement of U.S. Patent No. 7,157,447 through Lupin's filing of an Abbreviated New Drug Application (ANDA) seeking approval for a generic version of Xarelto.

2. Has U.S. Patent No. 7,157,447 been challenged in other proceedings? Yes, the patent has been subject to ex parte reexamination by the USPTO, which confirmed its patentability following amendments. It has also been challenged in other litigations with different generic manufacturers.

3. What is the typical duration of Xarelto's market exclusivity related to the asserted patent? U.S. Patent No. 7,157,447 was set to expire on March 7, 2024. Litigation aims to extend exclusivity beyond this date through injunctions or to secure early generic entry if successful.

4. Are settlements common in Xarelto patent litigation? Yes, many patent litigations involving Xarelto and other branded pharmaceuticals are resolved through confidential settlement agreements between the brand manufacturer and the generic company.

5. What happens if Lupin Limited is found to infringe the patent? If Lupin is found to infringe, the court may issue an injunction preventing Lupin from launching its generic rivaroxaban until the patent expires or is otherwise invalidated.

CITATIONS

[1] Complaint for Patent Infringement, Janssen Products, L.P. v. Lupin Limited, No. 2:10-cv-05954 (D.N.J. Sept. 27, 2010). [2] USPTO Reexamination Certificate, U.S. Patent No. 7,157,447 (issued Sept. 11, 2012). [3] Various filings in Janssen Products, L.P. v. Lupin Limited, No. 2:10-cv-05954 (D.N.J.). (Specific settlement terms are typically not publicly disclosed).